Analysis of HIV Type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry Inhibitors

AIDS Research and Human Retroviruses

Volumn 25, Issue 7, 2009, Pages 701-705

  Hudelson, Sarah E ^a   Marlowe, Natalia ^b   Huang, Wei ^c   Bruce, Robert ^b   Church, Jessica D ^a   Husnik, Marla ^d   Donnell, Deborah ^d   Coates, Thomas ^d   Jackson, J Brooks ^a   Chesney, Margaret ^e   Koblin, Beryl ^f   Eshleman, Susan H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Monogram Biosciences ^*

^c MONOGRAM BIOSCIENCES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NEW YORK BLOOD CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; UNITED STATES; VIRUS ENTRY;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TIME FACTORS; UNITED STATES;

EID: 70349199594     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0014     Document Type: Article

References (13)

1. Greenberg ML and Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-340.
2. Briz V, Poveda E, and Soriano V: HIV entry inhibitors: Mechanisms of action and resistance pathways. J Antimicrob Chemother 2006;57:619-627.
3. Koblin B, Chesney M, and Coates T: Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: The EXPLORE randomised controlled study. Lancet 2004;364:41-50.
4. Eshleman SH, Husnik M, Hudelson S, et al.: Analysis of antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men recently infected with HIV-1 in the United States: The EXPLORE Study. AIDS 2007;21:1165-1174.
5. Eshleman SH, Hudelson SE, Bruce R, et al.: Analysis of HIV type 1 gp41 sequences in diverse HIV-1 strains. AIDS Res Human Retroviruses 2007;23:1603-1608.
6. Stanford University HIV Drug Resistance Database: Fusion Inhibitor Resistance Notes. http:== hivdb.stanford.edu= cgi-bin= FIResiNote.cgi. Accessed 10= 6= 08.
7. Limoli K, Huang W, Toma J, et al.: Validation and performance characteristics of the PhenoSense HIV fusion inhibitor susceptibility assay. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, December 16-19, 2005. Abstract #H1076.
8. Loutfy MR, Raboud JM, Montaner JS, et al.: Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide. Antiviral Res 2007;75:58-63.
9. Carmona R, Perez-Alvarez L, Munoz M, et al.: Natural resistance- associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 2005;32:248-253.
10. Peuchant O, Capdepont S, Ragnaud JM, et al.: Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antiviral Ther 2007;12:559-562.
11. Roman F, Gonzalez D, Lambert C, et al.: Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 2003;33:134-139.
12. Holguin A, Faudon JL, Labernardiere JL, and Soriano V: Susceptibility of HIV-1 non-B subtypes and recombinant variants to enfuvirtide. J Clin Virol 2007;38:176-180.
13. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008;16:62-68.